Overview

• Swedish medical tech firm's Q4 revenue rose 16% yr/yr with 28% organic growth

• Q4 operating profit increased by 25% to SEK 92 mln

• Company expanded RayStation use in multiple cancer centers

Outlook

• RaySearch targets operating margin of at least 25% for full year 2026

• Company introduces new strategic function to strengthen market focus

• RaySearch sees strong demand across all regions despite geopolitical uncertainty

Result Drivers

• RAYSTATION EXPANSION - Expansion of RayStation in multiple cancer centers contributed to Q4 growth

• LICENSE SALES - Growing license sales and recurring support revenues provided revenue stability

• CURRENCY IMPACT - Strengthened Swedish krona significantly impacted reported net sales

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "strong buy"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

• Wall Street's median 12-month price target for RaySearch Laboratories AB (publ) is SEK330.00, about 88.1% above its February 11 closing price of SEK175.40

• The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release: ID:nMFN4TgQ8t

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.